Tag: PARP inhibitor

ICARE Social Media Post August 2023

 FDA Approval Post – Approves Niraparib 


A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial. Read more about the FDA approval at ⁠https://tinyurl.com/dzdvtm9m Learn more about the MAGNITUDE …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82423/

ICARE Social Media Post April 2023

PARP Inhibitors for Metastatic Prostate Cancer: Niraparib

A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35131040/⁠Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.

Permanent link to this article: https://inheritedcancer.net/post42023/

ICARE Social Media Post March 2023

Treatment for PALB2-associated breast cancer with Talazoparib

According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease. Read the full article at this link: https://www.nature.com/articles/s43018-022-00439-1 Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.

Permanent link to this article: https://inheritedcancer.net/post32723/